Interpace Biosciences, Inc.

As of June 30, 2026, Interpace Biosciences, Inc. carries a market capitalization of 225.76M, placing it among publicly traded companies globally. Its enterprise value stands at 224.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Interpace Biosciences, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Interpace Biosciences, Inc. has 5.54M shares outstanding.

As of June 30, 2026, Interpace Biosciences, Inc. trades at a trailing price-to-earnings ratio of 4.95. The price-to-sales ratio is 3.35, and the price-to-book ratio stands at 9.71.

As of June 30, 2026, Interpace Biosciences, Inc. trades at an EV/EBITDA multiple of 44.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 53.78 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 224.05M versus a market cap of 225.76M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Interpace Biosciences, Inc. maintains a current ratio of 2.22, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.19, indicating elevated leverage, while an interest coverage ratio of 120.45 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 104.29, measuring how efficiently the asset base is converted into earnings. The company generates approximately 346,695.44 in revenue per employee across its workforce of 104.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.73 indicates how many times Interpace Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Interpace Biosciences, Inc. recorded an income tax benefit of -20.86M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 4.00M, leaving 24.45M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 22, 2026, Interpace Biosciences, Inc.'s stock has declined approximately 68.45% over the past 52 weeks. The 50-day moving average sits at 28.30, while the 200-day moving average is 37.50.

Over the twelve months ended June 30, 2026, Interpace Biosciences, Inc. generated 36.14M in revenue and converted that into 24.45M in net income, yielding earnings per share of 4.49. EBITDA reached 5.06M, while operating income came in at 4.17M.

As of June 30, 2026, Interpace Biosciences, Inc. holds 2.69M in cash and equivalents against 974,000.00 in total debt, resulting in a net debt position of -2.69M. Total book value stands at 23.24M, with working capital of 6.02M providing operational flexibility.

Interpace Biosciences, Inc. produced 4.46M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -353,000.00 in capital expenditures, free cash flow totaled 4.10M - equivalent to 1.38 per share.

Over the twelve months ended June 30, 2026, Interpace Biosciences, Inc. posted a gross margin of 63.75, reflecting its pricing power and cost economics. The operating margin of 11.53 and net profit margin of 67.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.82, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Interpace Biosciences, Inc. shareholders.

Interpace Biosciences, Inc.'s most recent stock split took place on August 27, 2026 with a 5:1 split ratio.

As of June 30, 2026, Interpace Biosciences, Inc. has an Altman Z-Score of 5.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.